Thor Medical A (TRMED.OL) Osake Kurssi
Thor Medical A Kurssi
Liikevaihto on kasvanut 8,6 % vuodessa viimeisten 13 vuoden aikana 439 000,00 NOK:een. Thor Medical An nettomarginaali on nyt −13 214,8 %, noussut −14 470,5 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 5,10 NOK, eli yli nykyhintaa 14,9 %. 9 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
Thor Medical A osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Thor Medical A liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Thor Medical A -osakkeesta
The business model of Nordic Nanovector ASA focuses on the development and commercialization of targeted therapies for hematological cancers. The company specializes in the development of innovative antibody-radionuclide conjugates (ARCs), which deliver highly specific radiation directly to cancer cells. By targeting and effectively treating cancers such as non-Hodgkin’s lymphoma, Nordic Nanovector aims to improve patient outcomes and quality of life. The company’s dedication to research, development, and commercialization of novel therapies places it at the forefront of the fight against hematological cancers, making Nordic Nanovector a prominent player in the biotechnology industry.
Nordic Nanovector ASA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Nordic Nanovector ASA in the market are other companies operating in the field of targeted therapies for cancer treatment. However, Nordic Nanovector ASA maintains a unique position due to its innovative technology and product pipeline. With its lead candidate, Betalutin®, Nordic Nanovector ASA aims to provide a superior treatment option for patients suffering from non-Hodgkin's lymphoma. Despite facing competition, Nordic Nanovector ASA's strategic focus and ongoing advancements position it as a prominent player in the market.
Nordic Nanovector ASA is a biopharmaceutical company based in Norway. Founded in 2009, the company focuses on the development and commercialization of innovative targeted therapeutics for the treatment of hematological malignancies. Nordic Nanovector's flagship product candidate is Betalutin®, a novel radioimmunotherapy designed to improve patient outcomes in non-Hodgkin lymphoma. With a strong background in radioimmunotherapy and precision medicine, Nordic Nanovector aims to revolutionize cancer treatment by delivering more effective and less toxic therapies. Through strategic collaborations and continuous research and development efforts, the company strives to advance the field of precision oncology and bring hope to patients worldwide. Nordic Nanovector ASA continues to pursue its mission of improving cancer care and addressing unmet medical needs.
Nordic Nanovector ASA, a leading biotechnology company, has achieved several significant milestones. The company successfully completed the phase 1 clinical trial for its innovative targeted therapy, Betalutin, designed for the treatment of non-Hodgkin lymphoma (NHL). Furthermore, Nordic Nanovector ASA received Fast Track designation from the U.S. FDA for Betalutin, recognizing its potential to address unmet medical needs. The company also secured Orphan Drug Designation for Betalutin from both the FDA and the European Medicines Agency (EMA), providing further regulatory support. These achievements highlight Nordic Nanovector ASA's commitment to developing groundbreaking therapies and solidify its position as a key player in the field of oncology.
Nordic Nanovector ASA primarily operates in Norway, as it is a Norwegian biopharmaceutical company. However, the company's presence is not limited to Norway alone. Nordic Nanovector ASA has expanded its reach to other countries and regions as well, including the United States, throughout Europe, and Asia. With its focus on developing innovative targeted therapies for hematological cancers, Nordic Nanovector ASA is continuously seeking to collaborate with global partners and extend its presence in key markets worldwide.
Nordic Nanovector ASA represents a set of core values and a corporate philosophy that guides its operations. The company believes in innovation, scientific excellence, and a patient-centered approach. Nordic Nanovector is dedicated to developing targeted therapies for patients with hematological malignancies, aiming to improve their quality of life and overall survival. By leveraging its proprietary technology platform, the company aims to make a meaningful impact in the field of precision medicine. Nordic Nanovector ASA strives to collaborate with partners and stakeholders to accelerate the development of novel treatments and bring hope to patients in need.
Analyytikot asettavat tällä hetkellä Thor Medical A-osakkeelle keskimääräisen tavoitehinnan 5,10 NOK (mediaani: 5,10 NOK), mikä merkitsee +14,9 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.
9 analyytikkoa arvioi tällä hetkellä Thor Medical A-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Thor Medical A-yhtiöltä 20,00 M NOK liikevaihtoa ja −0,27 NOK osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Thor Medical A-osake noteerataan hintaan 0,42 EUR (4,44 NOK).
Thor Medical A-osake (TRMED.OL) on listattuna 5 pörssissä, muun muassa: London (0R6Y.L), SIX (Zürich) (8NN.SW), Frankfurt (8NN.F), München (8NN.MU), Düsseldorf (8NN.DU).
Nordic Nanovector ASA is a Norwegian company specializing in the development of innovative therapies for the treatment of non-Hodgkin lymphomas. The company operates with a unique business model based on scientific research and strategic partnerships. The company focuses on the development of innovative antibody therapies that target specific antigens of non-Hodgkin lymphomas. They also developed Betalutin®, a radioisotope-based conjugate that aims to selectively destroy cancer cells. Nordic Nanovector ASA works closely with strategic partners to advance the development and commercialization of its products, aiming to reduce costs and risks while increasing the reach and success of its products. In summary, Nordic Nanovector ASA develops innovative antibody therapies and radioisotope-based conjugates to fight non-Hodgkin lymphomas, working with strategic partners to drive product development and commercialization, and pursuing a research strategy focused on scientific excellence and long-term success.
odotettu liikevaihto Thor Medical A on 20,00 M NOK. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Thor Medical A on −63,73 M NOK. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Thor Medical A:n hinta-voitto-suhde (P/E) on tällä hetkellä −16,54. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Thor Medical A-osakkeen arvostusta.
Thor Medical A:n hinta-myynti-suhde (P/S) on tällä hetkellä 52,70. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Thor Medical A-osakkeen arvostuskennuslukuna.
Thor Medical A:n Eulpool-laatuscore on 3/10.
Thor Medical A:n ISIN on NO0010597883. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Thor Medical A:n WKN on A1H64K. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Thor Medical A:n ticker on TRMED.OL. Tämä pörssinoteeraus käytetään Thor Medical A-osakkeiden kauppaan pörssissä.
Thor Medical A osake
Thor Medical A vertaisryhmä
Thor Medical A Ticker
Thor Medical A FIGI
Kaikki tunnusluvut ja syvällinen analyysi Thor Medical A:sta
Meidän osakeanalyysimme Thor Medical A-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Thor Medical A:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: